Study of the Physiology of Pre-eclampsia and Vascular IUGR With Constitution of a Biological Collection
CPVP
1 other identifier
observational
500
1 country
1
Brief Summary
Preeclampsia and intrauterine growth retardation (IUGR) are serious and frequent pathologies, specific to pregnancy. They represent 70 000 new cases a year, or 9% of pregnancies and cause 50,000 premature births per year in France. The consequences in terms of morbidity and perinatal morbidity and the medical and economic costs make it an issue public health. Pre-eclampsia associates maternal hypertension with dysfunction kidney. There is no cure for pre-eclampsia or IUGR vascular during pregnancy. These pathologies invariably evolve towards a maternal and / or fetal aggravation sometimes very fast. Primary prevention and secondary education and screening for these pathologies are still insufficient. A better understanding of the pathophysiology of these placental vascular pathologies is necessary for the development of supported medical, obstetric and pediatric that will improve the state of health maternal and neonatal
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Aug 2018
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
August 6, 2018
CompletedFirst Submitted
Initial submission to the registry
August 8, 2018
CompletedFirst Posted
Study publicly available on registry
August 10, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 1, 2028
ExpectedStudy Completion
Last participant's last visit for all outcomes
August 1, 2028
June 12, 2026
June 1, 2026
10 years
August 8, 2018
June 11, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
genomic analysis on placenta
by chromatin immunoprecipitation-sequencing (ChIP-seq)
day of delivery
Secondary Outcomes (6)
genomic analysis on blood
day of delivery
genomic analysis on placenta
day of delivery
VEGF blood level
day of delivery
PLGF blood level
day of delivery
sFlt1 blood level
day of delivery
- +1 more secondary outcomes
Study Arms (2)
Vascular group
Pregnant women with vascular pathology
Control group
* Pregnancy without any vascular complication * Delivery before or after 37 weeks of gestation (GW) * In case of delivery after 37GW: birth by cesarean delivery
Interventions
collect of placenta, blood and urinary samples at delivery
Eligibility Criteria
pregnant women with or without vascular pathology
You may qualify if:
- pregnant women
- With or without vascular pathology
You may not qualify if:
- refusal to participate
- multiple pregnancy
- major fetal malformation diagnosed during pregnancy follow-up
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
CHi Creteil
Créteil, 94000, France
Biospecimen
Blood samples for maternal DNA sequencing and angiogenic factors (VEGF, PLGF, sFLt-1, sQDR) Urinary samples: Angiogenic factors Placenta: for placenta DNA sequencing and angiogenic factors
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Edouard Lecarpentier, MD PhD
CHI CRETEIL
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
August 8, 2018
First Posted
August 10, 2018
Study Start
August 6, 2018
Primary Completion (Estimated)
August 1, 2028
Study Completion (Estimated)
August 1, 2028
Last Updated
June 12, 2026
Record last verified: 2026-06
Data Sharing
- IPD Sharing
- Will not share